THE PHARMACOKINETICS AND CLINICAL IMPORTANCE OF POLYMORPHIC DRUG OXIDATION

被引：0

作者：

WILKINSON, GR ^{[1
]}

机构：

[1] VANDERBILT UNIV,DEPT PHARMACOL,NASHVILLE,TN 37232

来源：

EUROPEAN JOURNAL OF PHARMACOLOGY | 1990年 / 183卷 / 01期

关键词：

D O I：

10.1016/0014-2999(90)91310-8

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：59 / 59

页数：1

共 50 条

[1] CLINICAL CONSEQUENCES OF POLYMORPHIC DRUG OXIDATION
ALVAN, G
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1991, 5 (03) : 209 - 228
[2] INTERINDIVIDUAL DIFFERENCES IN DRUG OXIDATION - CLINICAL IMPORTANCE
SJOQVIST, F
VONBAHR, C
DRUG METABOLISM AND DISPOSITION, 1973, 1 (01) : 469 - 482
[3] Clinical importance of genetic polymorphism of drug oxidation
Edeki, T
MOUNT SINAI JOURNAL OF MEDICINE, 1996, 63 (5-6): : 291 - 300
[4] POLYMORPHIC DRUG OXIDATION IN HUMANS
EICHELBAUM, M
FEDERATION PROCEEDINGS, 1984, 43 (08) : 2298 - 2302
[5] Pharmacokinetics and polymorphic oxidation of dextromethorphan in a Japanese population
Nagai, N
Kawakubo, T
Kaneko, F
Ishii, M
Shinohara, R
Saito, Y
Shimamura, H
Ohnishi, A
Ogata, H
BIOPHARMACEUTICS & DRUG DISPOSITION, 1996, 17 (05) : 421 - 433
[6] PHARMACOKINETICS OF MIDAZOLAM IN RELATION TO POLYMORPHIC SPARTEINE OXIDATION
KLOTZ, U
MIKUS, G
ZEKORN, C
EICHELBAUM, M
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 22 (05) : 618 - 620
[7] PHARMACOKINETICS OF MIDAZOLAM IN RELATION TO POLYMORPHIC SPARTEINE OXIDATION
KLOTZ, U
MIKUS, G
ZEKORN, C
EICHELBAUM, M
ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1986, 59 : 117 - 117
[8] RECENT DEVELOPMENTS IN HEPATIC DRUG OXIDATION - IMPLICATIONS FOR CLINICAL PHARMACOKINETICS
BROSEN, K
CLINICAL PHARMACOKINETICS, 1990, 18 (03) : 220 - 239
[9] Importance of drug transporters in pharmacokinetics and drug safety
Ward, Peter
TOXICOLOGY MECHANISMS AND METHODS, 2008, 18 (01) : 1 - 10
[10] HETEROATOM POLYMORPHIC DRUG OXIDATION - SULFOXIDATION
HALEY, CS
IDLE, JR
MITCHELL, SC
SMITH, RL
WARING, RH
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (02) : P285 - P286

← 1 2 3 4 5 →